Newsroom

Sorted by: Latest

-

AM Best Affirms Credit Ratings of Delphi Financial Group, Inc. and Its Subsidiaries; Upgrades Issuer Credit Rating of Standard Security Life Insurance Company of New York

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of A++ (Superior) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “aa+” (Superior) of the life/health subsidiaries of Delphi Financial Group, Inc. (DFG) (Wilmington, DE): Reliance Standard Life Insurance Company (Schaumburg, IL) and First Reliance Standard Life Insurance Company (New York, NY) (together referred to as Reliance Standard). AM Best also has affirmed the FSR of A++ (Superior) and the...
-

Xtrackers UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Xtrackers Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-119.899 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 19 November 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, and...
-

Xtrackers (IE) plc UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Dublin, 19 November 2026 This announcement is to inform the shareholders of the sub-funds listed in the table below (each a Sub-Fund, and together the Sub-Funds) (the Shareholders) on behalf of the board of directors of the Co...
-

Resumen: Epitech Group y Horus Pharma firman un acuerdo de licencia a escala mundial para el desarrollo del adelmidrol en el ámbito de la salud ocular

NIZA, Francia--(BUSINESS WIRE)--Epitech Group S.p.A., sociedad biofarmacéutica italiana especializada en neuroinflamación, y Horus Pharma, laboratorio francés especializado en oftalmología, anuncian un acuerdo de licencia a escala mundial sobre el adelmidrol, una molécula de la familia de las ALIAmidas desarrollada por Epitech Group. Este acuerdo otorga a Horus Pharma los derechos exclusivos de desarrollo y comercialización del adelmidrol para aplicaciones en oftalmología humana y dermatología...
-

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter

SINGAPORE--(BUSINESS WIRE)--It creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene....
-

Xtrackers II UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Xtrackers II Investment company with variable capital (Société d'investissement à capital variable) Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg R.C.S. Luxembourg B-124.284 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Luxembourg, 19 November 2026 The board of directors of the Company (the “Board of Directors”) hereby informs all shareholders of the sub-funds listed in the table below (each a “Sub-Fund”, a...
-

Chattanooga Quantum Collaborative, The Company Lab, and Outset Ventures Join Forces to Accelerate Quantum Commercialization

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--A new Tennessee-New Zealand partnership gives quantum startups a pathway to commercial infrastructure, enterprise customers and global capital....
-

Charles Schwab Investment Management, Inc. UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions...
-

Purpose Investments Adds Anthropic and Micron to Yield Shares ETF Suite on Cboe Canada

TORONTO--(BUSINESS WIRE)--Cboe Canada welcomes Purpose Investments for the launch of two new yield-focused single-stock ETFs....
-

Sand Grove Capital Management LLP UK Regulatory Announcement: Form 8.3 Pollen Street Group Limited

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mu...